AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03686696
Drug: ARB
RxNorm normalized name: Arbli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
Trial: NCT01255306
Drug: Local medical treatment of raised intraocular pressure
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added.
Trial: NCT03199638
Drug: Glutamine vs. Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral supplementation with either glutamine or placebo twice daily for 3 months
Trial: NCT04939792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule ingested orally
Trial: NCT04939792
Drug: Vitamin D + L-cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule ingested orally
Trial: NCT02792517
Drug: Ethynil Estradiol/Norgestimate Oral Contraceptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethynil estradiol (EE)/norgestimate combination oral contraceptive is a 28-tablet cycle in which 1 oral tablet is taken daily; each containing 0.250 mg norgestimate and 0.035 mg EE for 21 days, after which a tablet only containing inert ingredients is taken for last 7 days of the 28 day cycle.
Trial: NCT00798577
Drug: Vigamox Ophthalmic Solution
RxNorm normalized name: Vigamox Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 5mg/mL 3 times daily for 7 days
Trial: NCT00798577
Drug: BSS placebo
RxNorm normalized name: BSS Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
Trial: NCT01412060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied in capsules.
Trial: NCT03097029
Drug: Pancreatic Enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
Trial: NCT02807844
Drug: MCS110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
Trial: NCT02807844
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
Trial: NCT02192502
Drug: HES 130/0.4 (Voluven)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00629525
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 at a dose of 10 mg PO daily
Trial: NCT00661102
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00661102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00661102
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00661102
Drug: dexpantenol [Bepantol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00753688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo 800 mg once daily orally
Trial: NCT01338935
Drug: CW 002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus.
Trial: NCT00385463
Drug: Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01688635
Drug: LY2963016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT01688635
Drug: US Approved Lantus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT00702910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator
Trial: NCT00702910
Drug: GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational drug or placebo
Trial: NCT00685841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID MDI
Trial: NCT05918588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule; Route of administration: oral
Trial: NCT02598635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
Trial: NCT01593228
Drug: Doxorubicin HCL liposome injection
RxNorm normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution~Route of administration: Intravenous
Trial: NCT04169854
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
Trial: NCT03321318
Drug: AK-R215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product is prescribed to all ofrandomized subjects
Trial: NCT03428451
Drug: NaCl 3% HS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
Trial: NCT03428451
Drug: NaCl 3% HS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
Trial: NCT03428451
Drug: NaCl 0.9% NS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
Trial: NCT01503632
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00119171
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00895453
Drug: classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
Trial: NCT02071069
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
Trial: NCT01183455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusions of placebo once a week for 12 weeks.
Trial: NCT02414958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02215824
Drug: BIWH 3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02215824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03256071
Drug: Modified BUCY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Trial: NCT01294982
Drug: AOBO-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
Trial: NCT01331720
Drug: hMG-HP
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00373100
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00373100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01319019
Drug: GSK961081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of different doses and dosing regimens of the drug
Trial: NCT01319019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm
Trial: NCT03926338
Drug: Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) and Celecoxib (oral 200mg twice daily for 3 months) followed by surgical resection.
Trial: NCT01146951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
Trial: NCT02762331
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparing safety and efficacy of IV Vitamin C in CABG patients
Trial: NCT02762331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intervention
Trial: NCT01446679
Drug: atrovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01187836
Drug: TRV120027
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
Trial: NCT01187836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered for 14 hours.
Trial: NCT03342937
Drug: Oxaliplatin+Capecitabine+Pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~1. Safety validation part: all Cycles are 21 days in length.~2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days.
Trial: NCT01329289
Drug: SOM230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg intramuscularly (IM) on day 1 of each 28 day cycle
Trial: NCT02728388
Drug: aminolevulinic acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Levulan Kerastick~Drug: Topical placebo~Device: Omnilux Revive~Procedure: Photodynamic therapy~Other: Tumor growth rate measurements
Trial: NCT03637517
Drug: DSM265-TPGS 34% SDD, 400 mg fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.
Trial: NCT03637517
Drug: DSM265-TPGS 34% SDD, 400 mg fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.
Trial: NCT03637517
Drug: DSM265 25% SDD, 400 mg fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation used in early clinical trials.
Trial: NCT03181841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double-blind oral intake of single doses of the aforementioned drug or placebo
Trial: NCT04426994
Drug: proton pump inhibitor use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients using long term proton pump inhibitor
Trial: NCT02504177
Drug: novel oral anticoagulant for 30 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
Trial: NCT02504177
Drug: novel oral anticoagulant for 24 hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
Trial: NCT03836352
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO (BID)
Trial: NCT02126670
Drug: Comp01
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02126670
Drug: Comp02
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02126670
Drug: Comp03
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02126670
Drug: Comp04
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04183387
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00665678
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment for three months with placebo
Trial: NCT00003595
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003595
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003595
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03357666
Drug: HUDC_VT(Glucose 200mg/Sodium chloride 200mg)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal administration, two tablets once a day for 7 days
Trial: NCT03357666
Drug: HUDC_VT (Glucose 400mg/Sodium chloride 200mg)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal administration, two tablets once a day for 7 days
Trial: NCT03357666
Drug: HUDC_VT (Glucose 400mg)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal administration, two tablets once a day for 7 days
Trial: NCT03357666
Drug: HUDC_VT (Sodium chloride 200mg)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal administration, two tablets once a day for 7 days
Trial: NCT03357666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration, two tablets once a day for 7 days
Trial: NCT00418730
Drug: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
RxNorm normalized name: tetrapeptide-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
Trial: NCT04087408
Drug: Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~2. doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~3. Trigger will be done using HCG followed by OPU 36 h later.~4. Retrieved oocytes will be fertilized by ICSI.~5. LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6. GnRH agonist 0.1 mg will be given 6 days after OPU for the study group.~7. Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~8. Quantative BHCG will be performed 14 days after OPU.
Trial: NCT00424346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03182413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03182413
Drug: THN102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00647257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
Trial: NCT00154219
Drug: Lumiracoxib (drug)
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04036929
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet
Trial: NCT02541734
Drug: Gelofusine
RxNorm normalized name: Gelofusine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of gelofusine
Trial: NCT02541734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00180843
Drug: nebulized saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02542787
Drug: VSN16R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule
Trial: NCT02022436
Drug: Contrast Ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
Trial: NCT01433471
Drug: Trichuris suis ova
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,500 eggs by mouth every two weeks for 12 weeks
Trial: NCT04604756
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of placebo (oral)
Trial: NCT03246451
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-4 tablets in 14 days
Trial: NCT01601418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
Trial: NCT00576589
Drug: CE-326,597
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.
Trial: NCT00576589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
Trial: NCT04499989
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 vaginal tablet of Placebo Comparator self inserted 12 hours before IUD insertion
Trial: NCT04883034
Drug: Analgesics, etoricoxibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anaelgetic oral intake
Trial: NCT01753167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
Trial: NCT01900743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
Trial: NCT00445770
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: up to 8 mg per week, oral dosing for 52 weeks
Trial: NCT05532280
Drug: Etoricoxib 90 mg film coated tablet
RxNorm normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an immediate-release tablet containing 90 mg of Etoricoxib
Trial: NCT05532280
Drug: Arcoxia 90 mg film coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an immediate-release tablet containing 90 mg of Etoricoxib
Trial: NCT02927938
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine-based consolidation chemotherapy
Trial: NCT03797456
Drug: ICP-022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-022 (tablets, 50 mg) is given orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.